Evaluation 2015: Exemplary Evaluations in a Multicultural World

View Printable Version

Process and Outcome Evaluation of Two Phased Innovation Award Programs at the National Institute of Allergy and Infectious Diseases

Session Number: 2012
Track: Research, Technology & Development Evaluation
Session Type: Poster
First Author or Discussion Group Leader: Liberty Walton [Public Health Analyst - NIH]
Second Author or Discussion Group Leader: Brandie Taylor [Supervisory Progam Analyst - National Institutes of Health]
Third Author or Discussion Group Leader: Krystal Tomlin [Health Policy Analyst - National Institutes of Health/NIAID]
Fourth Author or Discussion Group Leader: Dione Washington [NIH]
Time: Nov 11, 2015 (07:00 PM - 09:00 PM)
Room: Grand Ballroom, Poster 314

Other Authors: Jane C. Lockmuller, National Institutes of Health
Audience Level: None
Other Information: This group of submitters/presenters will be submitting 2 posters. If possible, can you please make sure these posters are scheduled beside each other in the conference room? The other posters is "An Exploration of the Impact of the Federal Workplace Built Environment on Employee Wellbeing and Productivity at the National Institute of Allergy and Infectious Diseases" (led by Krystal Tomlin).

Session Abstract: 

The National Institutes of Health (NIH) uses several approaches to promote and support high-risk, high-reward research. The National Institute of Allergy and Infectious Diseases (NIAID) at the NIH, promotes such research through a biphasic R21/R33 grant mechanism. This mechanism begins with a R21 grant which may lead to a R33 grant. Through the provision of these grants, NIAID aims to support high-risk, high-reward product-oriented research within the Division of AIDS (DAIDS). In particular, two DAIDS programs utilize this mechanism - the AIDS Vaccine Research (AVR) Program and the Microbicide Innovation Program (MIP). To determine if this biphasic grant mechanism is achieving its goal, The Madrillon Group Inc., under contract and in collaboration with NIAID’s Strategic Planning & Evaluation Branch/OSPIDA and DAIDS, conducted a process and outcome evaluation of these R21/R33 research programs. This poster illustrates the evaluation methodology, provides key study findings, and outlines lessons learned from this evaluation.

For questions or concerns about your event registration, please contact registration@eval.org or 202-367-1173.

For questions about your account, membership status, or help logging in, please contact info@eval.org.

Cancellation Policy: Refunds less a $50 fee will be granted for requests received in writing prior to 11:59 PM EDT October 6, 2015. Email cancellation requests to registration@eval.org. Fax request to (202) 367-2173. All refunds are processed after the meeting. After October 6, 2015 all sales are final.